Innovent Biologics, Inc. announced updated Phase 1 clinical data for IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma ...
AI antibody discovery can be accelerated by integrating computational prediction with experimental production, validation, ...
Researchers analyzed 44 Bundibugyo virus genomes and modeled how approved and experimental Ebola antibodies might bind the ...
Based on an integrated analysis of the efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) data from dose optimization cohorts receiving IBI3003 at 120, 360, and 540 µg/kg in the Phase 1 ...
Changchun High-Tech (000661.SZ) announced that its subsidiary, Changchun JinSai Pharmaceutical Co., Ltd. (referred to as ...
FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases HONG KONG and SHANGHAI and ...
Lung cancer is still the top cancer killer, but new developments are shifting what the future might hold for patients.
Lung cancer remains the deadliest malignancy worldwide, and non-small cell lung cancer (NSCLC) accounts for roughly 85 ...
Over the past decade, a succession of new GvHD treatments targeting different components of the immune response have been ...
More than 3 million Americans suffer from celiac disease, an illness with no current treatment. Is help on the way?
Healthcare Asia Magazine on MSN
Sclerosis treatment market to reach $44.45b by 2034 as cases rise
Asia Pacific is expected to see strong growth. The global multiple sclerosis treatment market is projected to grow to $44.45b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results